Friday, 3 July
08.00 Registration
09.00 Welcome and Introduction
Session I: Heart failure and arterial hypertension: evolving concepts in the pathophysiology and treatment
09.15 L1 Heart rate control in heart failure: old and new drugs, E. Agabiti-Rosei, Italy
09.40 L2 New perspectives on heart failure: Speaker to be announced
10.05 L3 Renal sympathetic denervation therapy for resistant hypertension, A. Coca, Spain
10.30 Question and answer
10.45 Coffee break
Session II: Heart and metabolism: beyond coronary heart disease
11.05 L4 The nature of Type 2 Diabetes: relationships to arterial & cardiac function and heart failure, K. Cruickshank, UK
11.25 L5 Diabetes and heart rate control dysfunction (Cardiac autonomic Neuropathy), E. Maddaloni, USA
11.50 L6 Cardiometabolic implications of thyroid dysfunction, M. Khamaisi, USA
12.20 Question and answer
12.35 Lunch
Session III: Diabetes: prevention and treatment issues
14.00 L7 Pre-diabetes: relevance and treatment, N. Napoli, Italy
14.25 L8 Diabetes management: how to choose the right drug?, R. Castañeda, Mexico
14.50 L9 Diabetes in pregnancy, Speaker to be announced
15.15 Question and answer
15.30 Coffee Break
Session IV: Complications
16.00 L10 Cardiovascular mortality in diabetes, H. Keenan, USA
16.25 L11 Cardiometabolic implications of antidiabetic drugs, Speaker to be announced
16.50 L12 Diabetic osteopathy and the bone-vascular axis, N. Napoli, Italy
17.15 Question and answer
17.30 Take home messages
Concluding remarks
Saturday, July 4
Session V: Thyroid: focus on old and new recommendations
09.00 L13 Thyroid nodules in clinical practice: from medical therapy to ultrasonically-guide intervention, Speaker to be announced
09.25 L14 Hypothyroidism and Hyperthyroidism in pregnancy, G. Brenta, Argentina
09.50 Question and answer
Session VI: Debate on hot topics
10.05 D1 Statins and diabetes: Pros, H. Keenan, USA
Statins and diabetes: Cons, E. Maddaloni, USA
10.45 D2 Subclinical hypothyroidism: to treat or not to treat? Pros, A. S. Caballero, Mexico
Subclinical hypothyroidism: to treat or not to treat? Cons, G. Brenta, Argentina
11.30 Coffee break
Session VII: The complexity of cardiometabolic disease
11.50 L16 Personalised therapy to manage the cardiometabolic patient, K. Cruickshank, UK
12.15 L17 Poly-pharmacotherapy: Compliance and Adherence, N. de La Garza, Mexico
12.40 Question and answer
12.55 Take home message
13.10 Closing remarks from the scientific organiser
13.15 End of the conference
Closing Lunch
